indication

First Episode Psychosis

Competitive landscape projected to Digital nudge’s launch window

as of 2026-07-01
Competitive set
7
5 approved · 2 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
52 events
2020
2024
2028
2032
2036
2040
2044
2048
today
Digital nudge launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 41 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 41 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 41 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugNot Yet Recruiting
Cannabidiol
Pipeline · Phase 3
Phase 31 trial
OwnerCentral Institute of Mental Health, Mannheim
Protection—
drugCompleted
Minocycline
Pipeline · Phase 2
Phase 21 trial
OwnerPakistan Institute of Living and Learning
Protection—

Market size

prevalence as a range, not a number